SeaStar Medical

SeaStar Medical is commercializing QUELIMMUNE for the treatment of acute kidney injury in children and reports a 77% survival rate without dialysis dependence at day 60 in pediatrics. The key value driver is the NEUTRALIZE-AKI study in adults (339 patients), which is more than 65% enrolled and is expected to complete by end-2026 or Q1 2027. A CMS billing code takes effect on October 1, 2026, and could facilitate reimbursement for adults. The company has roughly $6–7 million in cash, no long-term debt, and a market capitalization of about $15 million, so the stock is highly dependent on the outcome of the adult study. » More on de.investing.com

SeaStar Medical shareholders elected John Neuman to the board of directors and approved a revised omnibus incentive plan that increases authorized common shares from 207,046 to 896,546. They also confirmed WithumSmith+Brown as the independent auditor for the fiscal year ending December 31, 2026, and granted the board the right to adjourn the annual meeting if necessary. The stock last traded at $3.06 after a weekly gain of more than 16%, but is down roughly 68% year-to-date. SeaStar reported strong revenue growth in the first quarter of 2026, attributed to the product QUELIMMUNE, and has a current ratio of 2.73. » More on de.investing.com

SeaStar Medical recorded a 69% revenue rise in the first quarter of 2026 to US$495,000, driven by increased use of the QUELIMMUNE therapy for pediatric acute kidney injury. Gross margin remained above 90% with stable operating expenses of US$4.1 million; net loss narrowed slightly to US$3.5 million. The customer base grew to 17 hospitals, and the company is targeting about US$2 million in revenue for 2026 and an expansion of adult clinical trials. Investors reacted cautiously; the stock fell 3.57% in premarket trading. » More on de.investing.com